SlideShare a Scribd company logo
+
RENAL CELL
CARCINOMA-
ETIOLOGY,PATHOLOGY
DR G PRAVEEN CHANDRA
+
RCC in numbers
 Accounts for 2% to 3% of all adult malignant neoplasms
 The most lethal of the common urologic cancers.
 Five-year relative survival rates for patients diagnosed in 2002
to 2008 were 71% for kidney cancer, 78% for bladder cancer
(excluding carcinoma in situ), and 99% for prostate cancer
(Siegel et al, 2013).
+
 Approximately 65,000 new diagnoses of RCC are made each
year in the United States, and 13,000 patients die of disease
(Siegel et al,2013).
 Overall, approximately 12 new cases are diagnosed per
100,000 population per year, with a male-to-female
predominance of 3:2 (Siegel et al, 2013).
 This is primarily a disease of older adults, with typical
presentation between 50 and 70 years of age.
+
 However, diagnosis of renal cancer has increased more rapidly
in those less than 40 years of age than any other age group
(Nepple et al, 2012).
 Incidence rates are 10% to 20% higher and 5-year survival
rates 5% lower in African-Americans for unknown reasons
(Lipworth et al, 2006; Stafford et al, 2008; Chow et al,2013;
Siegel et al, 2013).
+
 The majority of cases of RCC are believed to be sporadic; only
2% to 3% are proven to be familial.
+
 The incidence of RCC has increased since the 1970s by an
average of 3% to 4% per year, largely related to the more
prevalent use of ultrasonography of abdominal complaints
+
 Although Wilms tumor is much more common in younger
children, RCC is as common as Wilms tumor during the second
decade of life.
+
ETIOLOGY
+
 RCCs were traditionally thought to arise primarily from the
proximal convoluted tubules, and this is probably true for the
clear cell and papillary variants.
 However, other histologic subtypes of RCC, such as
chromophobe RCC and collecting duct carcinoma, are derived
from the more distal components of the nephron
+
 The most general accepted environmental risk factor for RCC
is tobacco exposure ; Relative risk---1.4 to 2.5.
 Obesity is now accepted as another major risk factor for RCC,
with an increased relative risk of 1.07 for each additional unit of
body mass index.
+
 Hypertension appears to be the 3rd major etiologic
factor for RCC.
 The proposed mechanisms are hypertension induced renal
injury and inflammation or metabolic or functional changes in
the renal tubules that may increase susceptibility to
carcinogens
+
 A family history of RCC may also be a factor;
 One study showed a relative risk of 2.9 for individuals with a
first- or second-degree relative with RCC.
+
 Other potential iatrogenic causes include regular usage of
nonsteroidal anti-inflammatory drugs, which is associated with
a relative risk of 1.51,
 while aspirin and acetaminophen were not associated with any
increased risk (Cho et al, 2011).
+
 Retroperitoneal radiation therapy, typically administered for
Wilms tumor or testicular cancer, appears to be a risk factor for
RCC, although the relative risks are low (Romanenko et al,
2000).
+
 An increased incidence of RCC is also observed in patients
with end-stage renal disease and certain familial
syndromes.
+
FAMILIAL RCC subtypes
+
+
TUMOR BIOLOGY &
CLINICAL IMPLICATIONS
+
+
PATHOLOGY
+
 Most RCCs are round to ovoid and circumscribed by a
pseudocapsule of compressed parenchyma and fibrous tissue
rather than a true histologic capsule.
 Unlike upper tract urothelial carcinomas, most RCCs are not
grossly infiltrative, with the notable exception of collecting duct
carcinoma and sarcomatoid variants.
+
Size Matters…
 Tumor size has averaged between 4 and 8 cm in most series
but can vary from a few millimeters to large enough to fill the
entire abdomen.
 Tumors smaller than 3 cm were previously classified a benign
adenomas, but some small tumors have been associated with
metastases.
 With the exception of oncocytomas and some small (<5-mm)
low-grade papillary adenomas, there are no reliable histologic
or ultrastructural criteria to differentiate benign from malignant
renal epithelial tumors.
+
 When they are bivalved, RCCs consist of yellow, tan, or brown
tumor interspersed with fibrotic, necrotic, or hemorrhagic areas;
few are uniform in gross appearance.
 Cystic degeneration is found in 10% to 25% of RCCs and
appears to be associated with a better prognosis compared
with purely solid RCC.
 Calcification can be stippled or plaque like and is found in 10%
to 20% of RCCs.
+
 Nuclear features can be highly variable.
 Grading has been based primarily on nuclear size and shape
and the presence or absence of prominent nucleoli.
+
 Fuhrman’s system is an independent prognostic factor for RCC
generally and for clear cell RCC in particular.
 Recent evidence suggests that Fuhrman grade is also a
significant predictor of outcome for papillary RCC, but features
other than nuclear characteristics may form the basis of a
preferred scheme for chromophobe RCC
+ FUHRMAN’S CLASSIFICATION
SYSTEM FOR
NUCLEAR GRADE IN RCC
+
 Frank invasion and perforation of the renal capsule, renal
sinus, or collecting system are found in approximately 20% of
cases, although displacement of these structures is a more
common finding.
+
 One unique feature of RCC is its predilection for involvement of
the venous system, which is found in 10% of RCCs, more often
than in any other tumor type.
 This is most commonly manifested in the form of a contiguous
tumor thrombus that can extend into the inferior vena cava
(IVC) as high as the right atrium.
 Many such tumor thrombi are highly vascularized by arterial
blood flow, and some directly invade the wall of the renal vein
or vena cava, which correlates with compromised prognosis
+
 Most sporadic RCCs are unilateral and unifocal.
 Bilateral involvement can be synchronous or asynchronous and
is found in 2% to 4% of sporadic RCCs, although it is
considerably more common in patients with familial forms of
RCC, such as von Hippel-Lindau disease.
 Multicentricity, which is found in 10% to 20% of cases, is more
common in association with papillary histology and familial
RCC.
+
 Microsatellite analysis suggests a clonal origin for most
multifocal RCC within the same kidney, but tumor in the
contralateral kidney is likely to be an independent growth if it is
synchronous or a metastasis if it is asynchronous.
+
Clear Cell RCC
 Clear cell RCC accounts for 70% to 80% of all RCCs, formerly
known as “conventional” RCC.
 These tumors are typically yellow when they are bivalved and
are highly vascular, containing a network of delicate vascular
sinusoids interspersed between sheets or acini of tumor cells.
 On microscopic examination, clear cell RCC can include clear
cell, granular cell, or mixed types.
+
+
 In general, patients with clear cell RCC have a worse
prognosis compared with papillary or chromophobe RCC,
even after stratification for stage and grade.
+
Papillary Renal Cell Carcinoma
 Also designated chromophilic RCC in previous classification
schemes
 The 2nd most common histologic subtype .
 It represents 10% to 15%of all RCCs.
+
+
Chromophobe
Renal Cell Carcinoma
 First described in 1985
 A distinctive histologic subtype of RCC that represents 5% of all
RCCs.
 Appears to be derived from the cortical portion of the collecting
duct
+
 A perinuclear clearing or “halo” is typically found
 Electron microscopic findings consist of numerous 150- to 300-
nm microvesicles, which are the single most distinctive and
defining feature of chromophobe cell carcinoma.
 These microvesicles characteristically stain positive for Hale
colloidal iron, indicating the presence of a mucopolysaccharide
unique to chromophobe RCC.
+
+
 Most studies of the clinical behavior of chromophobe RCC
suggest a better prognosis for localized chromophobe RCC
than for clear cell RCC
 but a poor outcome in the subset of patients with sarcomatoid
features or metastatic disease.
+
Collecting Duct Carcinoma
 Carcinoma of the collecting ducts of Bellini is a relatively rare
subtype of RCC, accounting for less than 1% of all RCCs
 Most reported cases of collecting duct carcinoma have been
high grade, advanced stage, and unresponsive to
conventional therapies
+
Renal Medullary Carcinoma
 Renal medullary carcinoma is a subtype of RCC that occurs
almost exclusively in patients with the sickle cell trait.
 It is typically diagnosed in young African-Americans, often in
the third decade of life, and many cases are both locally
advanced and metastatic at the time of diagnosis.
 This tumor shares many histologic features with collecting duct
carcinoma, and some consider it a subtype of collecting duct
carcinoma or at least a closely related tumor.
+
Sarcomatoid Differentiation
 Sarcomatoid differentiation is found in 1%-5% of RCCs
 Most commonly in association with clear cell RCC or
chromophobe RCC.
 Sarcomatoid differentiation is characterized by
 spindle cell histology,
 positive staining for vimentin,
 infiltrative growth pattern,
 aggressive local and metastatic behaviour &
 poor prognosis.
+
+
Unclassified
Renal Cell Carcinoma
 Unclassified RCC represents a small minority of cases (1% to
5%) of presumed RCC
 Features remain indeterminate even after careful analysis.
 Poorly differentiated
 Associated with a highly aggressive biologic behaviour &
 A particularly poor prognosis.
+
Clinical Presentation
 Because of the sequestered location of the kidney within the
retroperitoneum, many renal masses remain asymptomatic and
nonpalpable until they are locally advanced.
 With the more pervasive use of noninvasive imaging for the
evaluation of a variety of nonspecific symptom complexes,
more than 60% of RCCs are now detected incidentally
+
+
 A less common but important presentation of RCC is that of
spontaneous perirenal hemorrhage, in which the underlying
mass may be obscured.
 More than 50% of patients with perirenal hematoma of unclear
etiology have an occult renal tumor, most often AML or RCC.
+
 Paraneoplastic syndromes are found in 10% to 20% of patients
with RCC, and few tumors are associated with the diversity of
such syndromes.
 In fact, RCC was previously referred to as the internist’s
tumor because of the predominance of systemic rather than
local manifestations.
 Now, a more appropriate name would be the radiologist’s
tumor, given the frequency of incidental detection
+
+
 Hypercalcemia has been reported in up to 13% of patients with
RCC and can be due to either paraneoplastic phenomena or
osteolytic metastatic involvement of the bone.
+
 The signs and symptoms of hypercalcemia are often
nonspecific and include nausea, anorexia fatigue, and
decreased deep tendon reflexes.
 Medical management predominates and includes vigorous
hydration followed by diuresis with furosemide and the
selective use of bisphosphonates, corticosteroids, or calcitonin.
+
 Bisphosphonate therapy is now established as a standard of
care for patients with hypercalcemia of malignancy, as long as
renal function is adequate.
 Zoledronic acid, 4 mg intravenously every 4 weeks, appears to
be particularly effective in patients with RCC but must be
withheld in the presence of renal insufficiency
+
 Hypertension and polycythemia are other important
paraneoplastic syndromes commonly found in patients with
RCC
+
 One of the more fascinating paraneoplastic syndromes
associated with RCC is nonmetastatic hepatic dysfunction, or
Stauffer syndrome, which has been reported in 3% to
20% of cases.
 Almost all patients with Stauffer syndrome have an elevated serum
alkaline phosphatase level,
 67% have elevated prothrombin time or hypoalbuminemia &
 20% to 30% have elevated serum bilirubin or transaminase
+
 In general, treatment of paraneoplastic syndromes associated
with RCC has required surgical excision or systemic therapy
and, except for hypercalcemia, medical therapies have not
proved helpful.
+
SCREENING
 A number of factors make screening for RCC appealing.
 Most important, RCC remains primarily a surgical disease
requiring early diagnosis to optimize the opportunity for cure.
+
 The primary factor that limits the widespread implementation of
screening for RCC is the relatively low incidence of RCC in the
general population (approximately 12 cases per 100,000
population per year)
+
 For now, however, the focus of screening for RCC must be on
well-defined target populations, such as patients with end-stage
renal disease and acquired renal cystic disease, tuberous
sclerosis, and familial RCC.
+
+
THANK YOU

More Related Content

What's hot

Approach & Interpretation of Liver Biopsy
Approach & Interpretation of Liver BiopsyApproach & Interpretation of Liver Biopsy
Approach & Interpretation of Liver Biopsy
Dr. Indranil Bhattacharya
 
KIDNEY MESENCHYMAL TUMORS
KIDNEY MESENCHYMAL TUMORSKIDNEY MESENCHYMAL TUMORS
KIDNEY MESENCHYMAL TUMORS
Sindhuja Yella
 
cytology of the breast
cytology of the breastcytology of the breast
cytology of the breast
Hayelom kassaye
 
Pathology ca bladder
Pathology   ca bladderPathology   ca bladder
Pathology ca bladder
dr vipin Drvipinsharma3
 
Soft tissue-tumors-2012
Soft tissue-tumors-2012Soft tissue-tumors-2012
Soft tissue-tumors-2012
fikri asyura
 
Spindle cell lesions of the breast diagnostic issues 2019 (1)
Spindle cell lesions of the breast  diagnostic issues 2019 (1)Spindle cell lesions of the breast  diagnostic issues 2019 (1)
Spindle cell lesions of the breast diagnostic issues 2019 (1)
Alejandro Palacio
 
Cystic disease of the kidney
Cystic disease of the kidneyCystic disease of the kidney
Cystic disease of the kidney
Hofstra Northwell School of Medicine
 
Bethesda system for reporting
Bethesda system for reportingBethesda system for reporting
Renal pathology lecture 4 Tumors of kidney and urinary tract. Sufia Husain 2020
Renal pathology lecture 4 Tumors of kidney and urinary tract. Sufia Husain 2020Renal pathology lecture 4 Tumors of kidney and urinary tract. Sufia Husain 2020
Renal pathology lecture 4 Tumors of kidney and urinary tract. Sufia Husain 2020
Sufia Husain
 
Recent Advances:Hepatocellular Nodules
Recent Advances:Hepatocellular NodulesRecent Advances:Hepatocellular Nodules
Recent Advances:Hepatocellular Nodules
Dr Niharika Singh
 
Yokohama system cytology
Yokohama system cytologyYokohama system cytology
Yokohama system cytology
BPS GMC (W) KHANPUR KALAN SONEPAT
 
INFANCY & CHILDHOOD TUMOR
INFANCY & CHILDHOOD TUMORINFANCY & CHILDHOOD TUMOR
INFANCY & CHILDHOOD TUMOR
Dr. Roopam Jain
 
Prostate grossing and reporting
Prostate grossing and reportingProstate grossing and reporting
Prostate grossing and reporting
Malini Goswami
 
THYROID - cytology pptx
THYROID - cytology pptxTHYROID - cytology pptx
THYROID - cytology pptx
KalaivaniGanapathy
 
Pediatric Renal Tumors
Pediatric Renal TumorsPediatric Renal Tumors
Pediatric Renal Tumors
Utsab Das
 
Role of cytology in renal lesions
Role of cytology in renal lesionsRole of cytology in renal lesions
Role of cytology in renal lesions
Manan Shah
 
Myofibroblasts in health and disease
Myofibroblasts in health and diseaseMyofibroblasts in health and disease
Myofibroblasts in health and disease
Ruchi Sharma
 
Squash smear cytology - By Anamika dev
Squash smear cytology - By Anamika devSquash smear cytology - By Anamika dev
Squash smear cytology - By Anamika dev
Anamika Dev
 
Gi polyps
Gi polypsGi polyps
Testicular biopsy
Testicular biopsyTesticular biopsy
Testicular biopsydrsadia
 

What's hot (20)

Approach & Interpretation of Liver Biopsy
Approach & Interpretation of Liver BiopsyApproach & Interpretation of Liver Biopsy
Approach & Interpretation of Liver Biopsy
 
KIDNEY MESENCHYMAL TUMORS
KIDNEY MESENCHYMAL TUMORSKIDNEY MESENCHYMAL TUMORS
KIDNEY MESENCHYMAL TUMORS
 
cytology of the breast
cytology of the breastcytology of the breast
cytology of the breast
 
Pathology ca bladder
Pathology   ca bladderPathology   ca bladder
Pathology ca bladder
 
Soft tissue-tumors-2012
Soft tissue-tumors-2012Soft tissue-tumors-2012
Soft tissue-tumors-2012
 
Spindle cell lesions of the breast diagnostic issues 2019 (1)
Spindle cell lesions of the breast  diagnostic issues 2019 (1)Spindle cell lesions of the breast  diagnostic issues 2019 (1)
Spindle cell lesions of the breast diagnostic issues 2019 (1)
 
Cystic disease of the kidney
Cystic disease of the kidneyCystic disease of the kidney
Cystic disease of the kidney
 
Bethesda system for reporting
Bethesda system for reportingBethesda system for reporting
Bethesda system for reporting
 
Renal pathology lecture 4 Tumors of kidney and urinary tract. Sufia Husain 2020
Renal pathology lecture 4 Tumors of kidney and urinary tract. Sufia Husain 2020Renal pathology lecture 4 Tumors of kidney and urinary tract. Sufia Husain 2020
Renal pathology lecture 4 Tumors of kidney and urinary tract. Sufia Husain 2020
 
Recent Advances:Hepatocellular Nodules
Recent Advances:Hepatocellular NodulesRecent Advances:Hepatocellular Nodules
Recent Advances:Hepatocellular Nodules
 
Yokohama system cytology
Yokohama system cytologyYokohama system cytology
Yokohama system cytology
 
INFANCY & CHILDHOOD TUMOR
INFANCY & CHILDHOOD TUMORINFANCY & CHILDHOOD TUMOR
INFANCY & CHILDHOOD TUMOR
 
Prostate grossing and reporting
Prostate grossing and reportingProstate grossing and reporting
Prostate grossing and reporting
 
THYROID - cytology pptx
THYROID - cytology pptxTHYROID - cytology pptx
THYROID - cytology pptx
 
Pediatric Renal Tumors
Pediatric Renal TumorsPediatric Renal Tumors
Pediatric Renal Tumors
 
Role of cytology in renal lesions
Role of cytology in renal lesionsRole of cytology in renal lesions
Role of cytology in renal lesions
 
Myofibroblasts in health and disease
Myofibroblasts in health and diseaseMyofibroblasts in health and disease
Myofibroblasts in health and disease
 
Squash smear cytology - By Anamika dev
Squash smear cytology - By Anamika devSquash smear cytology - By Anamika dev
Squash smear cytology - By Anamika dev
 
Gi polyps
Gi polypsGi polyps
Gi polyps
 
Testicular biopsy
Testicular biopsyTesticular biopsy
Testicular biopsy
 

Similar to Rcc1

Ajr%2 e155%2e4%2e2119098
Ajr%2 e155%2e4%2e2119098Ajr%2 e155%2e4%2e2119098
Ajr%2 e155%2e4%2e2119098
drzin
 
Kidney tumors
Kidney tumorsKidney tumors
Kidney tumors
walajavaraprasad
 
renal cell carcinoma radiology
renal cell carcinoma radiologyrenal cell carcinoma radiology
renal cell carcinoma radiology
docaashishgupt
 
Staging and investigation of ca kidney and bladder
Staging and investigation of ca kidney and bladderStaging and investigation of ca kidney and bladder
Staging and investigation of ca kidney and bladder
AtulGupta369
 
Renal tumors
Renal tumorsRenal tumors
Renal tumors
ShrutiDevendra
 
Renal tumors.pptx
Renal tumors.pptxRenal tumors.pptx
Renal tumors.pptx
Lara Masri
 
rccclass-160824074458.pptx
rccclass-160824074458.pptxrccclass-160824074458.pptx
rccclass-160824074458.pptx
Islah Raoof
 
Rcc and bladder cancer
Rcc and bladder cancerRcc and bladder cancer
Rcc and bladder cancer
Jwan AlSofi
 
Rcc by dr shiv
Rcc by dr shivRcc by dr shiv
Rcc by dr shiv
shiv kishor
 
Colo-rectal Carcinoma at a glance !!!
Colo-rectal Carcinoma at  a glance !!!Colo-rectal Carcinoma at  a glance !!!
Colo-rectal Carcinoma at a glance !!!
Suman Baral
 
Renal_cell_carcinoma_ppt_Akhil.pptx
Renal_cell_carcinoma_ppt_Akhil.pptxRenal_cell_carcinoma_ppt_Akhil.pptx
Renal_cell_carcinoma_ppt_Akhil.pptx
Akhilesh Maurya
 
Staging and investigation of hepatobillary ca
Staging and investigation of hepatobillary caStaging and investigation of hepatobillary ca
Staging and investigation of hepatobillary ca
AtulGupta369
 
Malignant tumours of the salivary glands
Malignant tumours of the salivary glandsMalignant tumours of the salivary glands
Malignant tumours of the salivary glandsShekhar Krishna Debnath
 
Surgical_Management_CCC.pdf
Surgical_Management_CCC.pdfSurgical_Management_CCC.pdf
Surgical_Management_CCC.pdf
Chrysi Tsiouri
 
Urology 5th year, 3rd lecture (extended/detailed version) (Dr. Ali Kamal)
Urology 5th year, 3rd lecture (extended/detailed version) (Dr. Ali Kamal)Urology 5th year, 3rd lecture (extended/detailed version) (Dr. Ali Kamal)
Urology 5th year, 3rd lecture (extended/detailed version) (Dr. Ali Kamal)
College of Medicine, Sulaymaniyah
 
Rcc by ramu
Rcc by ramuRcc by ramu
Rcc by ramu
damuluri ramu
 
CRC for 5th.
CRC for 5th.CRC for 5th.
CRC for 5th.
Shaikhani.
 
RCC- Staging and treatment of Renal Cell Carcinoma
RCC- Staging and treatment of Renal Cell CarcinomaRCC- Staging and treatment of Renal Cell Carcinoma
RCC- Staging and treatment of Renal Cell Carcinoma
Be Akash Sah
 
Tumor of kidney and urinary tract
Tumor of kidney and urinary tractTumor of kidney and urinary tract
Tumor of kidney and urinary tractessamramdan
 

Similar to Rcc1 (20)

Ajr%2 e155%2e4%2e2119098
Ajr%2 e155%2e4%2e2119098Ajr%2 e155%2e4%2e2119098
Ajr%2 e155%2e4%2e2119098
 
Kidney tumors
Kidney tumorsKidney tumors
Kidney tumors
 
renal cell carcinoma radiology
renal cell carcinoma radiologyrenal cell carcinoma radiology
renal cell carcinoma radiology
 
Staging and investigation of ca kidney and bladder
Staging and investigation of ca kidney and bladderStaging and investigation of ca kidney and bladder
Staging and investigation of ca kidney and bladder
 
Renal tumors
Renal tumorsRenal tumors
Renal tumors
 
Renal tumors.pptx
Renal tumors.pptxRenal tumors.pptx
Renal tumors.pptx
 
rccclass-160824074458.pptx
rccclass-160824074458.pptxrccclass-160824074458.pptx
rccclass-160824074458.pptx
 
Rcc and bladder cancer
Rcc and bladder cancerRcc and bladder cancer
Rcc and bladder cancer
 
Rcc by dr shiv
Rcc by dr shivRcc by dr shiv
Rcc by dr shiv
 
Colo-rectal Carcinoma at a glance !!!
Colo-rectal Carcinoma at  a glance !!!Colo-rectal Carcinoma at  a glance !!!
Colo-rectal Carcinoma at a glance !!!
 
Renal_cell_carcinoma_ppt_Akhil.pptx
Renal_cell_carcinoma_ppt_Akhil.pptxRenal_cell_carcinoma_ppt_Akhil.pptx
Renal_cell_carcinoma_ppt_Akhil.pptx
 
Staging and investigation of hepatobillary ca
Staging and investigation of hepatobillary caStaging and investigation of hepatobillary ca
Staging and investigation of hepatobillary ca
 
Malignant tumours of the salivary glands
Malignant tumours of the salivary glandsMalignant tumours of the salivary glands
Malignant tumours of the salivary glands
 
Renal malignancies
Renal  malignanciesRenal  malignancies
Renal malignancies
 
Surgical_Management_CCC.pdf
Surgical_Management_CCC.pdfSurgical_Management_CCC.pdf
Surgical_Management_CCC.pdf
 
Urology 5th year, 3rd lecture (extended/detailed version) (Dr. Ali Kamal)
Urology 5th year, 3rd lecture (extended/detailed version) (Dr. Ali Kamal)Urology 5th year, 3rd lecture (extended/detailed version) (Dr. Ali Kamal)
Urology 5th year, 3rd lecture (extended/detailed version) (Dr. Ali Kamal)
 
Rcc by ramu
Rcc by ramuRcc by ramu
Rcc by ramu
 
CRC for 5th.
CRC for 5th.CRC for 5th.
CRC for 5th.
 
RCC- Staging and treatment of Renal Cell Carcinoma
RCC- Staging and treatment of Renal Cell CarcinomaRCC- Staging and treatment of Renal Cell Carcinoma
RCC- Staging and treatment of Renal Cell Carcinoma
 
Tumor of kidney and urinary tract
Tumor of kidney and urinary tractTumor of kidney and urinary tract
Tumor of kidney and urinary tract
 

More from Praveen Ganji

Nccn nmibc
Nccn nmibcNccn nmibc
Nccn nmibc
Praveen Ganji
 
Ca prostate presentation1
Ca prostate presentation1Ca prostate presentation1
Ca prostate presentation1
Praveen Ganji
 
Testicular tumors treatment
Testicular tumors treatmentTesticular tumors treatment
Testicular tumors treatment
Praveen Ganji
 
Study designs & amp; trials presentation1 2
Study designs & amp; trials presentation1 2Study designs & amp; trials presentation1 2
Study designs & amp; trials presentation1 2
Praveen Ganji
 
Nccn prostate presentation1
Nccn prostate presentation1Nccn prostate presentation1
Nccn prostate presentation1
Praveen Ganji
 
Metabolic evaluation of urinary lithiasis 2
Metabolic evaluation of urinary lithiasis 2Metabolic evaluation of urinary lithiasis 2
Metabolic evaluation of urinary lithiasis 2
Praveen Ganji
 
Surgically correctable hypertension
Surgically correctable hypertensionSurgically correctable hypertension
Surgically correctable hypertension
Praveen Ganji
 
Endo bph
Endo bphEndo bph
Endo bph
Praveen Ganji
 
Ln in ca penis
Ln in ca penisLn in ca penis
Ln in ca penis
Praveen Ganji
 
Perinatal hdn f recovered file 1
Perinatal hdn f recovered file 1 Perinatal hdn f recovered file 1
Perinatal hdn f recovered file 1
Praveen Ganji
 
Dtpa in pujo
Dtpa in pujoDtpa in pujo
Dtpa in pujo
Praveen Ganji
 
Pheo presentation 3 2 18
Pheo presentation 3 2 18Pheo presentation 3 2 18
Pheo presentation 3 2 18
Praveen Ganji
 
Incidentaloma adrenal
Incidentaloma adrenalIncidentaloma adrenal
Incidentaloma adrenal
Praveen Ganji
 
Urodynamic studies (1)
Urodynamic studies (1)Urodynamic studies (1)
Urodynamic studies (1)
Praveen Ganji
 

More from Praveen Ganji (14)

Nccn nmibc
Nccn nmibcNccn nmibc
Nccn nmibc
 
Ca prostate presentation1
Ca prostate presentation1Ca prostate presentation1
Ca prostate presentation1
 
Testicular tumors treatment
Testicular tumors treatmentTesticular tumors treatment
Testicular tumors treatment
 
Study designs & amp; trials presentation1 2
Study designs & amp; trials presentation1 2Study designs & amp; trials presentation1 2
Study designs & amp; trials presentation1 2
 
Nccn prostate presentation1
Nccn prostate presentation1Nccn prostate presentation1
Nccn prostate presentation1
 
Metabolic evaluation of urinary lithiasis 2
Metabolic evaluation of urinary lithiasis 2Metabolic evaluation of urinary lithiasis 2
Metabolic evaluation of urinary lithiasis 2
 
Surgically correctable hypertension
Surgically correctable hypertensionSurgically correctable hypertension
Surgically correctable hypertension
 
Endo bph
Endo bphEndo bph
Endo bph
 
Ln in ca penis
Ln in ca penisLn in ca penis
Ln in ca penis
 
Perinatal hdn f recovered file 1
Perinatal hdn f recovered file 1 Perinatal hdn f recovered file 1
Perinatal hdn f recovered file 1
 
Dtpa in pujo
Dtpa in pujoDtpa in pujo
Dtpa in pujo
 
Pheo presentation 3 2 18
Pheo presentation 3 2 18Pheo presentation 3 2 18
Pheo presentation 3 2 18
 
Incidentaloma adrenal
Incidentaloma adrenalIncidentaloma adrenal
Incidentaloma adrenal
 
Urodynamic studies (1)
Urodynamic studies (1)Urodynamic studies (1)
Urodynamic studies (1)
 

Recently uploaded

A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
Dr. Jyothirmai Paindla
 
Vision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of opticsVision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of optics
Sai Sailesh Kumar Goothy
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley LifesciencesPharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Yodley Lifesciences
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}
NEHA GUPTA
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Dr. Jyothirmai Paindla
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
Lighthouse Retreat
 

Recently uploaded (20)

A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
 
Vision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of opticsVision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of optics
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley LifesciencesPharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
 

Rcc1

  • 2. + RCC in numbers  Accounts for 2% to 3% of all adult malignant neoplasms  The most lethal of the common urologic cancers.  Five-year relative survival rates for patients diagnosed in 2002 to 2008 were 71% for kidney cancer, 78% for bladder cancer (excluding carcinoma in situ), and 99% for prostate cancer (Siegel et al, 2013).
  • 3. +  Approximately 65,000 new diagnoses of RCC are made each year in the United States, and 13,000 patients die of disease (Siegel et al,2013).  Overall, approximately 12 new cases are diagnosed per 100,000 population per year, with a male-to-female predominance of 3:2 (Siegel et al, 2013).  This is primarily a disease of older adults, with typical presentation between 50 and 70 years of age.
  • 4. +  However, diagnosis of renal cancer has increased more rapidly in those less than 40 years of age than any other age group (Nepple et al, 2012).  Incidence rates are 10% to 20% higher and 5-year survival rates 5% lower in African-Americans for unknown reasons (Lipworth et al, 2006; Stafford et al, 2008; Chow et al,2013; Siegel et al, 2013).
  • 5. +  The majority of cases of RCC are believed to be sporadic; only 2% to 3% are proven to be familial.
  • 6. +  The incidence of RCC has increased since the 1970s by an average of 3% to 4% per year, largely related to the more prevalent use of ultrasonography of abdominal complaints
  • 7. +  Although Wilms tumor is much more common in younger children, RCC is as common as Wilms tumor during the second decade of life.
  • 9. +  RCCs were traditionally thought to arise primarily from the proximal convoluted tubules, and this is probably true for the clear cell and papillary variants.  However, other histologic subtypes of RCC, such as chromophobe RCC and collecting duct carcinoma, are derived from the more distal components of the nephron
  • 10. +  The most general accepted environmental risk factor for RCC is tobacco exposure ; Relative risk---1.4 to 2.5.  Obesity is now accepted as another major risk factor for RCC, with an increased relative risk of 1.07 for each additional unit of body mass index.
  • 11. +  Hypertension appears to be the 3rd major etiologic factor for RCC.  The proposed mechanisms are hypertension induced renal injury and inflammation or metabolic or functional changes in the renal tubules that may increase susceptibility to carcinogens
  • 12. +  A family history of RCC may also be a factor;  One study showed a relative risk of 2.9 for individuals with a first- or second-degree relative with RCC.
  • 13. +  Other potential iatrogenic causes include regular usage of nonsteroidal anti-inflammatory drugs, which is associated with a relative risk of 1.51,  while aspirin and acetaminophen were not associated with any increased risk (Cho et al, 2011).
  • 14. +  Retroperitoneal radiation therapy, typically administered for Wilms tumor or testicular cancer, appears to be a risk factor for RCC, although the relative risks are low (Romanenko et al, 2000).
  • 15. +  An increased incidence of RCC is also observed in patients with end-stage renal disease and certain familial syndromes.
  • 17. +
  • 19. +
  • 21. +  Most RCCs are round to ovoid and circumscribed by a pseudocapsule of compressed parenchyma and fibrous tissue rather than a true histologic capsule.  Unlike upper tract urothelial carcinomas, most RCCs are not grossly infiltrative, with the notable exception of collecting duct carcinoma and sarcomatoid variants.
  • 22. + Size Matters…  Tumor size has averaged between 4 and 8 cm in most series but can vary from a few millimeters to large enough to fill the entire abdomen.  Tumors smaller than 3 cm were previously classified a benign adenomas, but some small tumors have been associated with metastases.  With the exception of oncocytomas and some small (<5-mm) low-grade papillary adenomas, there are no reliable histologic or ultrastructural criteria to differentiate benign from malignant renal epithelial tumors.
  • 23. +  When they are bivalved, RCCs consist of yellow, tan, or brown tumor interspersed with fibrotic, necrotic, or hemorrhagic areas; few are uniform in gross appearance.  Cystic degeneration is found in 10% to 25% of RCCs and appears to be associated with a better prognosis compared with purely solid RCC.  Calcification can be stippled or plaque like and is found in 10% to 20% of RCCs.
  • 24. +  Nuclear features can be highly variable.  Grading has been based primarily on nuclear size and shape and the presence or absence of prominent nucleoli.
  • 25. +  Fuhrman’s system is an independent prognostic factor for RCC generally and for clear cell RCC in particular.  Recent evidence suggests that Fuhrman grade is also a significant predictor of outcome for papillary RCC, but features other than nuclear characteristics may form the basis of a preferred scheme for chromophobe RCC
  • 26. + FUHRMAN’S CLASSIFICATION SYSTEM FOR NUCLEAR GRADE IN RCC
  • 27. +  Frank invasion and perforation of the renal capsule, renal sinus, or collecting system are found in approximately 20% of cases, although displacement of these structures is a more common finding.
  • 28. +  One unique feature of RCC is its predilection for involvement of the venous system, which is found in 10% of RCCs, more often than in any other tumor type.  This is most commonly manifested in the form of a contiguous tumor thrombus that can extend into the inferior vena cava (IVC) as high as the right atrium.  Many such tumor thrombi are highly vascularized by arterial blood flow, and some directly invade the wall of the renal vein or vena cava, which correlates with compromised prognosis
  • 29. +  Most sporadic RCCs are unilateral and unifocal.  Bilateral involvement can be synchronous or asynchronous and is found in 2% to 4% of sporadic RCCs, although it is considerably more common in patients with familial forms of RCC, such as von Hippel-Lindau disease.  Multicentricity, which is found in 10% to 20% of cases, is more common in association with papillary histology and familial RCC.
  • 30. +  Microsatellite analysis suggests a clonal origin for most multifocal RCC within the same kidney, but tumor in the contralateral kidney is likely to be an independent growth if it is synchronous or a metastasis if it is asynchronous.
  • 31. + Clear Cell RCC  Clear cell RCC accounts for 70% to 80% of all RCCs, formerly known as “conventional” RCC.  These tumors are typically yellow when they are bivalved and are highly vascular, containing a network of delicate vascular sinusoids interspersed between sheets or acini of tumor cells.  On microscopic examination, clear cell RCC can include clear cell, granular cell, or mixed types.
  • 32. +
  • 33. +  In general, patients with clear cell RCC have a worse prognosis compared with papillary or chromophobe RCC, even after stratification for stage and grade.
  • 34. + Papillary Renal Cell Carcinoma  Also designated chromophilic RCC in previous classification schemes  The 2nd most common histologic subtype .  It represents 10% to 15%of all RCCs.
  • 35. +
  • 36. + Chromophobe Renal Cell Carcinoma  First described in 1985  A distinctive histologic subtype of RCC that represents 5% of all RCCs.  Appears to be derived from the cortical portion of the collecting duct
  • 37. +  A perinuclear clearing or “halo” is typically found  Electron microscopic findings consist of numerous 150- to 300- nm microvesicles, which are the single most distinctive and defining feature of chromophobe cell carcinoma.  These microvesicles characteristically stain positive for Hale colloidal iron, indicating the presence of a mucopolysaccharide unique to chromophobe RCC.
  • 38. +
  • 39. +  Most studies of the clinical behavior of chromophobe RCC suggest a better prognosis for localized chromophobe RCC than for clear cell RCC  but a poor outcome in the subset of patients with sarcomatoid features or metastatic disease.
  • 40. + Collecting Duct Carcinoma  Carcinoma of the collecting ducts of Bellini is a relatively rare subtype of RCC, accounting for less than 1% of all RCCs  Most reported cases of collecting duct carcinoma have been high grade, advanced stage, and unresponsive to conventional therapies
  • 41. + Renal Medullary Carcinoma  Renal medullary carcinoma is a subtype of RCC that occurs almost exclusively in patients with the sickle cell trait.  It is typically diagnosed in young African-Americans, often in the third decade of life, and many cases are both locally advanced and metastatic at the time of diagnosis.  This tumor shares many histologic features with collecting duct carcinoma, and some consider it a subtype of collecting duct carcinoma or at least a closely related tumor.
  • 42. + Sarcomatoid Differentiation  Sarcomatoid differentiation is found in 1%-5% of RCCs  Most commonly in association with clear cell RCC or chromophobe RCC.  Sarcomatoid differentiation is characterized by  spindle cell histology,  positive staining for vimentin,  infiltrative growth pattern,  aggressive local and metastatic behaviour &  poor prognosis.
  • 43. +
  • 44. + Unclassified Renal Cell Carcinoma  Unclassified RCC represents a small minority of cases (1% to 5%) of presumed RCC  Features remain indeterminate even after careful analysis.  Poorly differentiated  Associated with a highly aggressive biologic behaviour &  A particularly poor prognosis.
  • 45. + Clinical Presentation  Because of the sequestered location of the kidney within the retroperitoneum, many renal masses remain asymptomatic and nonpalpable until they are locally advanced.  With the more pervasive use of noninvasive imaging for the evaluation of a variety of nonspecific symptom complexes, more than 60% of RCCs are now detected incidentally
  • 46. +
  • 47. +  A less common but important presentation of RCC is that of spontaneous perirenal hemorrhage, in which the underlying mass may be obscured.  More than 50% of patients with perirenal hematoma of unclear etiology have an occult renal tumor, most often AML or RCC.
  • 48. +  Paraneoplastic syndromes are found in 10% to 20% of patients with RCC, and few tumors are associated with the diversity of such syndromes.  In fact, RCC was previously referred to as the internist’s tumor because of the predominance of systemic rather than local manifestations.  Now, a more appropriate name would be the radiologist’s tumor, given the frequency of incidental detection
  • 49. +
  • 50. +  Hypercalcemia has been reported in up to 13% of patients with RCC and can be due to either paraneoplastic phenomena or osteolytic metastatic involvement of the bone.
  • 51. +  The signs and symptoms of hypercalcemia are often nonspecific and include nausea, anorexia fatigue, and decreased deep tendon reflexes.  Medical management predominates and includes vigorous hydration followed by diuresis with furosemide and the selective use of bisphosphonates, corticosteroids, or calcitonin.
  • 52. +  Bisphosphonate therapy is now established as a standard of care for patients with hypercalcemia of malignancy, as long as renal function is adequate.  Zoledronic acid, 4 mg intravenously every 4 weeks, appears to be particularly effective in patients with RCC but must be withheld in the presence of renal insufficiency
  • 53. +  Hypertension and polycythemia are other important paraneoplastic syndromes commonly found in patients with RCC
  • 54. +  One of the more fascinating paraneoplastic syndromes associated with RCC is nonmetastatic hepatic dysfunction, or Stauffer syndrome, which has been reported in 3% to 20% of cases.  Almost all patients with Stauffer syndrome have an elevated serum alkaline phosphatase level,  67% have elevated prothrombin time or hypoalbuminemia &  20% to 30% have elevated serum bilirubin or transaminase
  • 55. +  In general, treatment of paraneoplastic syndromes associated with RCC has required surgical excision or systemic therapy and, except for hypercalcemia, medical therapies have not proved helpful.
  • 56. + SCREENING  A number of factors make screening for RCC appealing.  Most important, RCC remains primarily a surgical disease requiring early diagnosis to optimize the opportunity for cure.
  • 57. +  The primary factor that limits the widespread implementation of screening for RCC is the relatively low incidence of RCC in the general population (approximately 12 cases per 100,000 population per year)
  • 58. +  For now, however, the focus of screening for RCC must be on well-defined target populations, such as patients with end-stage renal disease and acquired renal cystic disease, tuberous sclerosis, and familial RCC.
  • 59. +